trial · primary record
Efgartigimod IV
Generalized Myasthenia Gravis
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2027-03 |
| Primary endpoint | Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Clearance (CL) |
| Registry ID | NCT04833894 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:09.720Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04833894
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.